Robert J Fontana

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1993754/robert-j-fontana-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

228 20,426 64 141 h-index g-index citations papers 6.1 6.56 23,623 255 L-index ext. citations avg, IF ext. papers

#	Paper	IF	Citations
228	Impact of Prior Drug Allergies on the Risk, Clinical Features, and Outcomes of Idiosyncratic Drug-Induced Liver Injury in Adults <i>Digestive Diseases and Sciences</i> , 2022 , 1	4	O
227	One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial <i>Kidney International Reports</i> , 2022 , 7, 241-250	4.1	0
226	A Revised Electronic Version of RUCAM for the Diagnosis of Drug Induced Liver Injury <i>Hepatology</i> , 2022 ,	11.2	9
225	Drug-induced liver injury 2022 , 462-470		
224	The Utility of Noninvasive PET/CT Myocardial Perfusion Imaging in Adult Liver Transplant Candidates <i>Transplantation Direct</i> , 2022 , 8, e1311	2.3	1
223	The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 20, 417-425	7.3	0
222	Clinical and Neurologic Outcomes in Acetaminophen-Induced Acute Liver Failure: A 21-Year Multicenter Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2615-2625.e3	6.9	3
221	Management of the Patient with Fulminant Hepatic Failure Awaiting Liver Transplantation 2021 , 143-1	51	
220	Marijuana use among adult liver transplant candidates and recipients. <i>Clinical Transplantation</i> , 2021 , 35, e14312	3.8	1
219	Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. <i>GastroHep</i> , 2021 , 3, 196-208	1	
218	Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. <i>Liver International</i> , 2021 , 41, 1884-1893	7.9	3
217	Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury. <i>Hepatology</i> , 2021 , 73, 268-281	11.2	19
216	A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma. <i>Oncologist</i> , 2021 , 26, 133-138	5.7	19
215	Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature. <i>Drug and Alcohol Dependence</i> , 2021 , 218, 10	8426	8
214	HLA-B*35:01 and Green Tea-Induced Liver Injury. <i>Hepatology</i> , 2021 , 73, 2484-2493	11.2	8
213	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , 2021 , 73, 2124-2140	11.2	8
212	Bariatric surgery and the risk of alcohol-related cirrhosis and alcohol misuse. <i>Liver International</i> , 2021 , 41, 1012-1019	7.9	3

(2020-2021)

211	Prognostic Value of the C-Methacetin Breath Test in Adults with Acute Liver Failure and Non-acetaminophen Acute Liver Injury. <i>Hepatology</i> , 2021 , 74, 961-972	11.2	О
210	Guillain-Barr Syndrome After COVID-19 mRNA Vaccination in a Liver Transplantation Recipient With Favorable Treatment Response. <i>Liver Transplantation</i> , 2021 ,	4.5	5
209	Combining K-72 Hepatic Failure with 15 Individual T-Codes to Identify Patients with Idiosyncratic Drug-Induced Liver Injury in the Electronic Medical Record. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	
208	Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure. <i>Hepatology</i> , 2021 , 74, 937-949	11.2	5
207	Potential Treatments for SARS-CoV-2 Infection. Clinical Liver Disease, 2020, 15, 181-186	2.2	4
206	United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. <i>Toxicology Reports</i> , 2020 , 7, 386-402	4.8	55
205	Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 457-468	6.1	5
204	Acute Liver Failure (ALF) in Pregnancy: How Much Is Pregnancy Related?. <i>Hepatology</i> , 2020 , 72, 1366-13	771.2	15
203	Management of Acute Liver Failure 2020 , 523-531		
202	Utility of a Computerized ICD-10 Algorithm to Identify Idiosyncratic Drug-Induced Liver Injury Cases in the Electronic Medical Record. <i>Drug Safety</i> , 2020 , 43, 371-377	5.1	4
201	Liver safety assessment in clinical trials of new agents for chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 96-109	3.4	3
200	Gender Disparities in Patients With Alcoholic Liver Disease Evaluated for Liver Transplantation. <i>Transplantation</i> , 2020 , 104, 293-298	1.8	8
199	Re: Distinguishing Between Sex and Gender Is Critical for Research in Transplantation. <i>Transplantation</i> , 2020 , 104, e58	1.8	
198	Role of Hepatitis E Virus Infection in North American Patients With Severe Acute Liver Injury. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00273	4.2	O
197	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020 , 114, 102514	15.5	14
196	Comparison of clinical outcomes and impact of SVR in American and Chinese patients with chronic hepatitis C. <i>JHEP Reports</i> , 2020 , 2, 100136	10.3	2
195	Incidence and Sequelae of Liver Injury Among Children Treated for Solid Tumors: Analysis of a Large Single-Center Prospective Cohort. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020 , 71, 197-202	2.8	1
194	Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 ,	12.7	28

193	Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcohol-Associated Cirrhosis. <i>Alcoholism: Clinical and Experimental Research</i> , 2019 , 43, 334-341	3.7	13
192	Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and Canada. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz175	1	3
191	Impact of a Prohibitive Versus Restrictive Tobacco Policy on Liver Transplant Candidate Outcomes. Liver Transplantation, 2019 , 25, 1165-1176	4.5	2
190	The Contents of Herbal and Dietary Supplements Implicated in Liver Injury in the United States Are Frequently Mislabeled. <i>Hepatology Communications</i> , 2019 , 3, 792-794	6	13
189	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2541-2551.e2	6.9	15
188	Constitutive release of CPS1 in bile and its role as a protective cytokine during acute liver injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 9125-9134	11.5	17
187	Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 2645-2652	4	5
186	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019 , 156, 1707-1716.e2	13.3	59
185	Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1195-	1204	23
184	Sclerosing Cholangitis-Like Changes on Magnetic Resonance Cholangiography in Patients With Drug Induced Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 789-790	6.9	7
183	The diagnosis and management of idiosyncratic drug-induced liver injury. <i>Liver International</i> , 2019 , 39, 31-41	7.9	26
182	Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis. Hepatology International, 2019 , 13, 641-648	8.8	20
181	Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 800-808	6.1	26
180	Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-NaWe, HCV-Infected Patients with APRI II in a Single-Arm, Open-Label, Multicenter Study. <i>Advances in Therapy</i> , 2019 , 36, 3458-3470	4.1	6
179	Severe Acute Hepatitis Attributed to the Herbal and Dietary Supplement OxyELITE Pro. <i>Clinical Liver Disease</i> , 2019 , 14, 45-48	2.2	2
178	AuthorN Response to Letter to the Editor: Noninvasive Intracranial Pressure Assessment in Acute Liver Failure. <i>Neurocritical Care</i> , 2019 , 30, 497	3.3	O
177	Antimicrobials and Antiepileptics Are the Leading Causes of Idiosyncratic Drug-induced Liver Injury in American Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019 , 69, 152-159	2.8	9
176	Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1753-1763	0.7	5

(2017-2019)

175	Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. <i>Hepatology</i> , 2019 , 69, 760-773	11.2	114
174	The high burden of alcoholic cirrhosis in privately insured persons in the United States. <i>Hepatology</i> , 2018 , 68, 872-882	11.2	110
173	Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia. <i>Hepatology</i> , 2018 , 67, 1003-1013	11.2	20
172	Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis. <i>Journal of Substance Abuse Treatment</i> , 2018 , 91, 20-27	4.2	29
171	Drug-Induced Liver Injury 2018 , 468-493		3
170	Noninvasive Intracranial Pressure Assessment in Acute Liver Failure. <i>Neurocritical Care</i> , 2018 , 29, 280-29	9 9 .3	36
169	Bleeding complications in acute liver failure. <i>Hepatology</i> , 2018 , 67, 1931-1942	11.2	50
168	Celecoxib-induced Liver Injury: Analysis of Published Case Reports and Cases Reported to the Food and Drug Administration. <i>Journal of Clinical Gastroenterology</i> , 2018 , 52, 114-122	3	7
167	Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group. <i>PLoS ONE</i> , 2018 , 13, e0206389	3.7	15
166	Liver Injury Associated with Sporting Activities. Seminars in Liver Disease, 2018, 38, 357-365	7.3	1
165	A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 615-625	4	6
164	HBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 113-122	6.9	23
163	Vemurafenib-induced granulomatous hepatitis. <i>Hepatology</i> , 2017 , 65, 745-748	11.2	16
162	Introducing the AASLD president: Anna S.F. Lok. <i>Hepatology</i> , 2017 , 65, 1084-1087	11.2	
161	Heat stroke leading to acute liver injury & failure: A case series from the Acute Liver Failure Study Group. <i>Liver International</i> , 2017 , 37, 509-513	7.9	30
160	Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury. <i>Liver International</i> , 2017 , 37, 1723-1730	7.9	16
159	Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. <i>Journal of Immunotoxicology</i> , 2017 , 14, 31-38	3.1	25
158	Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study.	3	12

157	Death and liver transplantation within 2 years of onset of drug-induced liver injury. <i>Hepatology</i> , 2017 , 66, 1275-1285	11.2	58
156	Temporal Changes in the Modes of Hepatitis C Virus Transmission in the USA and Northern China. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 2141-2149	4	3
155	Association of Variants of Arginine Vasopressin and Arginine Vasopressin Receptor 1A With Severe Acetaminophen Liver Injury. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2017 , 3, 500-505	7.9	7
154	Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation. <i>Liver Transplantation</i> , 2017 , 23, 968-971	4.5	10
153	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017 , 152, 1078-1089	13.3	137
152	Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. <i>Hepatology</i> , 2017 , 65, 1267-1277	11.2	65
151	Protocol based invasive intracranial pressure monitoring in acute liver failure: feasibility, safety and impact on management. <i>Critical Care</i> , 2017 , 21, 178	10.8	23
150	Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1382-1388	0.7	36
149	Identification and Characterization of Fenofibrate-Induced Liver Injury. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 3596-3604	4	33
148	Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury. <i>Hepatology</i> , 2017 , 65, 710-721	11.2	47
147	Reply. <i>Hepatology</i> , 2017 , 65, 389-390	11.2	
146	Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. <i>Liver International</i> , 2017 , 37, 757-764	7.9	35
145	An Immunoassay to Rapidly Measure Acetaminophen Protein Adducts Accurately Identifies Patients With Acute Liver Injury or Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 555-562.6	e 3 .9	45
144	Management of Acute Liver Failure 2017 , 551-560		
143	Risk of Liver Injury Associated with Green Tea Extract in SLIMQUICK([]) Weight Loss Products: Results from the DILIN Prospective Study. <i>Drug Safety</i> , 2016 , 39, 749-54	5.1	15
142	Fatigue in Patients with Chronic Hepatitis B Living in North America: Results from the Hepatitis B Research Network (HBRN). <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1186-96	4	17
141	Amoxicillin-Clavulanate-Induced Liver Injury. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 2406-2416	4	62
140	Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. <i>Hepatology</i> , 2016 , 63, 1493-505	11.2	345

139	Response to Collyer et al. American Journal of Gastroenterology, 2016, 111, 297-8	0.7	
138	Liver injury from nonsteroidal anti-inflammatory drugs in the United States. <i>Liver International</i> , 2016 , 36, 603-9	7.9	46
137	Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. <i>Liver Transplantation</i> , 2016 , 22, 505-15	4.5	53
136	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2016 , 22, 446-58	4.5	66
135	Outcomes in Adults With Acute Liver Failure Between 1998 and 2013: An Observational Cohort Study. <i>Annals of Internal Medicine</i> , 2016 , 164, 724-32	8	188
134	Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 2741-8	4	31
133	Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. <i>Hepatology</i> , 2015 , 61, 1485-94	11.2	183
132	Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1676-82.e1	6.9	34
131	Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study. <i>Liver International</i> , 2015 , 35, 370-80	7.9	50
130	Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. <i>Gastroenterology</i> , 2015 , 148, 1340-52.e7	13.3	466
129	Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury. <i>BMC Medicine</i> , 2015 , 13, 196	11.4	15
128	Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). <i>Liver International</i> , 2015 , 35, 1623-32	7.9	34
127	Persistent liver biochemistry abnormalities are more common in older patients and those with		
	cholestatic drug induced liver injury. American Journal of Gastroenterology, 2015 , 110, 1450-9	0.7	71
126		0.7	7 ¹ 280
	cholestatic drug induced liver injury. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1450-9 Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after		
126	cholestatic drug induced liver injury. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1450-9 Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. <i>Gastroenterology</i> , 2015 , 148, 108-17 Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at	13.3	280
126 125	cholestatic drug induced liver injury. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1450-9 Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. <i>Gastroenterology</i> , 2015 , 148, 108-17 Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 193-201.e1 Clinical and histologic features of azithromycin-induced liver injury. <i>Clinical Gastroenterology and</i>	13.3	280

121	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015 , 149, 649-59	13.3	622
120	Reply: To PMID 26116807. <i>Gastroenterology</i> , 2015 , 149, 1990-1	13.3	
119	New Onset Bloody Diarrhea in a Liver Transplant Recipient. New Onset Bloody Diarrhea in a Liver Transplant Recipient. <i>Gastroenterology</i> , 2015 , 149, 300-1	13.3	O
118	Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. <i>Hepatology</i> , 2014 , 60, 679-86	11.2	152
117	Epstein-Barr virus (EBV) related acute liver failure: a case series from the US Acute Liver Failure Study Group. <i>Digestive Diseases and Sciences</i> , 2014 , 59, 1630-7	4	54
116	Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. <i>Hepatology</i> , 2014 , 60, 1399-408	11.2	250
115	Carbamoyl phosphate synthetase-1 is a rapid turnover biomarker in mouse and human acute liver injury. <i>American Journal of Physiology - Renal Physiology</i> , 2014 , 307, G355-64	5.1	27
114	Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. <i>Journal of Hepatology</i> , 2014 , 60, 872-84	13.4	52
113	Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. <i>Gastroenterology</i> , 2014 , 146, 914-28	13.3	174
112	ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>American Journal of Gastroenterology</i> , 2014 , 109, 950-66; quiz 967	0.7	469
111	Acetaminophen overdose: What practitioners need to know. Clinical Liver Disease, 2014, 4, 17-21	2.2	9
110	Clinical features, diagnosis, and natural history of drug-induced liver injury. <i>Seminars in Liver Disease</i> , 2014 , 34, 134-44	7.3	48
109	Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. <i>Hepatology</i> , 2014 , 59, 661-70	11.2	249
108	Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. <i>Gastroenterology</i> , 2014 , 147, 96-108.e4	13.3	142
107	Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1550-5	6.9	29
106	Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival. <i>Hepatology International</i> , 2013 , 7, 990-9	8.8	13
105	Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 1766-75	4	23
104	Evaluation of the patient with chronic hepatitis B. <i>Clinical Liver Disease</i> , 2013 , 2, 1-4	2.2	

Drug-Induced Liver Injury Research Networks **2013**, 713-723

102	Liver injury from tumor necrosis factor-lantagonists: analysis of thirty-four cases. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 558-564.e3	6.9	151
101	Quality of life is significantly impaired in long-term survivors of acute liver failure and particularly in acetaminophen-overdose patients. <i>Liver Transplantation</i> , 2013 , 19, 991-1000	4.5	26
100	Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. <i>PLoS ONE</i> , 2013 , 8, e81974	3.7	50
99	Short and long-term outcomes in patients with acute liver failure due to ischemic hepatitis. Digestive Diseases and Sciences, 2012, 57, 777-85	4	41
98	YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. <i>Liver International</i> , 2012 , 32, 665-74	7.9	18
97	Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. <i>Liver Transplantation</i> , 2012 , 18, 1053-9	4.5	60
96	Managing drug-drug interactions with boceprevir and telaprevir. Clinical Liver Disease, 2012, 1, 36-40	2.2	4
95	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. <i>Pharmacogenetics and Genomics</i> , 2012 , 22, 784-95	1.9	96
94	Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. <i>Annals of Internal Medicine</i> , 2012 , 156, 857-60, W297-300	8	39
93	Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. <i>Gastroenterology</i> , 2011 , 141, 338-47	13.3	359
92	Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. <i>Gastroenterology</i> , 2011 , 141, 1665-72.e1-9	13.3	256
91	Mechanisms of drug-induced liver injury: from bedside to bench. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 8, 202-11	24.2	187
90	Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011 , 53, 182-9	2.8	59
89	No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. <i>Journal of Affective Disorders</i> , 2011 , 129, 205-12	6.6	4
88	Autoimmune acute liver failure: proposed clinical and histological criteria. <i>Hepatology</i> , 2011 , 53, 517-26	11.2	188
87	Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2011 , 106, 884-93	0.7	8
86	Drug-Induced Liver Injury 2011 , 478-506		

85	Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. <i>Gut</i> , 2010 , 59, 1401-9	19.2	81
84	Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1551-60	0.7	11
83	Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. <i>Gastroenterology</i> , 2010 , 138, 2321-31, 2331.e1-2	13.3	32
82	Entecavir in decompensated HBV cirrhosis: the future is looking brighter. <i>Journal of Hepatology</i> , 2010 , 52, 147-9	13.4	18
81	Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. <i>Hepatology</i> , 2010 , 51, 2117-26	11.2	239
80	Polymerase Igene POLG determines the risk of sodium valproate-induced liver toxicity. <i>Hepatology</i> , 2010 , 52, 1791-6	11.2	159
79	Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2949-58	0.7	45
78	Making the world a safer place. <i>Seminars in Liver Disease</i> , 2009 , 29, 335-6	7.3	2
77	Side effects of long-term oral antiviral therapy for hepatitis B. <i>Hepatology</i> , 2009 , 49, S185-95	11.2	206
76	Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. <i>Gastroenterology</i> , 2009 , 137, 856-64, 864.e1	13.3	438
75	Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. <i>Drug Safety</i> , 2009 , 32, 55-68	5.1	308
74	Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 219-26	6.9	39
73	Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <i>Gastroenterology</i> , 2008 , 135, 1924-34, 1934.e1-4	13.3	620
72	Assessment of the newly diagnosed patient with chronic hepatitis B virus infection. <i>American Journal of Medicine</i> , 2008 , 121, S22-32	2.4	2
71	Acute liver failure including acetaminophen overdose. <i>Medical Clinics of North America</i> , 2008 , 92, 761-94, viii	7	147
70	Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 1403-11	6.9	32
69	Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2766-75	0.7	35
68	Should aciclovir be given to all patients presenting with acute liver failure of unknown etiology?. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 298-9		3

(2006-2008)

67	Acute liver failure due to drugs. Seminars in Liver Disease, 2008, 28, 175-87	7.3	51
66	Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure. <i>Liver Transplantation</i> , 2008 , 14, 1498-504	4.5	70
65	Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. <i>Hepatology</i> , 2008 , 47, 789-98	11.2	139
64	Reply:. <i>Hepatology</i> , 2008 , 48, 689-690	11.2	1
63	Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. <i>Hepatology</i> , 2008 , 48, 1175-83	11.2	134
62	Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. <i>Hepatology</i> , 2007 , 45, 1154-63	11.2	35
61	Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. <i>Liver Transplantation</i> , 2007 , 13, 1100-8	4.5	86
60	Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2437-43	0.7	58
59	Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. <i>Critical Care Medicine</i> , 2007 , 35, 2498-508	1.4	325
58	Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. <i>Journal of Hepatology</i> , 2007 , 46, 420-31	13.4	112
57	A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report. <i>Journal of Medical Case Reports</i> , 2007 , 1, 88	1.2	16
56	Reply:. <i>Hepatology</i> , 2006 , 43, 882-882	11.2	1
55	Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. <i>Hepatology</i> , 2006 , 44, 925-35	11.2	48
54	Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. <i>Hepatology</i> , 2006 , 44, 1589-97	11.2	140
53	Immune thrombocytopenic purpura following liver transplantation: a case series and review of the literature. <i>Liver Transplantation</i> , 2006 , 12, 781-91	4.5	27
52	Valganciclovir for cytomegalovirus prophylaxis in liver transplant recipients. <i>Liver Transplantation</i> , 2006 , 12, 1022-1023	4.5	3
51	Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. <i>American Journal of Gastroenterology</i> , 2006 , 101, 983-92	0.7	52
50	Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2006 , 28, 1346-61	2.1	22

49	Management of drug-resistant chronic hepatitis B. Clinics in Liver Disease, 2006, 10, 275-302, viii	4.6	10
48	Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. <i>Gastroenterology</i> , 2006 , 130, 687-94	13.3	216
47	Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified?. <i>Gastroenterology</i> , 2006 , 130, 1357-62	13.3	7
46	Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. <i>Gastroenterology</i> , 2006 , 131, 1440-51	13.3	74
45	The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. <i>Gastrointestinal Endoscopy</i> , 2006 , 64, 855-64	5.2	85
44	Virologic response and resistance to adefovir in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2006 , 44, 283-90	13.4	286
43	Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2005 , 42, 218-24	13.4	363
42	Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. <i>Journal of Hepatology</i> , 2005 , 43, 614-22	13.4	69
41	Reply:. <i>Hepatology</i> , 2005 , 42, 739-740	11.2	2
40	Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. <i>Hepatology</i> , 2005 , 42, 1364-72	11.2	1352
39	Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. <i>Liver Transplantation</i> , 2005 , 11, 1581-9	4.5	240
38	Acute liver failure due to amoxicillin and amoxicillin/clavulanate. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 1785-90	4	64
37	Management of decompensated HBV cirrhosis: lamivudine and beyond. <i>American Journal of Gastroenterology</i> , 2004 , 99, 64-7	0.7	2
36	Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond. <i>Gastroenterology Clinics of North America</i> , 2004 , 33, 527-47, viii	4.4	6
35	Clinical significance of hepatitis B virus genotypes, variants, and mutants. <i>Clinics in Liver Disease</i> , 2004 , 8, 321-52, vi	4.6	49
34	Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2004 , 2, 183-97	6.9	16
33	Cytokine gene polymorphisms in chronic hepatitis B: a step up the immunology ladder. <i>American Journal of Gastroenterology</i> , 2003 , 98, 6-8	0.7	24
32	Renal transplantation in HBsAg+ patients: is lamivudine your "final answer"?. <i>Journal of Clinical Gastroenterology</i> , 2003 , 37, 9-11	3	4

31	Management of patients with decompensated HBV cirrhosis. Seminars in Liver Disease, 2003, 23, 89-100	7.3	42
30	A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. <i>Hepatology</i> , 2003 , 38, 518-26	11.2	2736
29	A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. <i>Liver Transplantation</i> , 2003 , 9, 49-56	4.5	54
28	Are we ready for marginal hepatitis B core antibody-positive living liver donors?. <i>Liver Transplantation</i> , 2003 , 9, 833-6	4.5	5
27	The Role of Optimism/Pessimism in HRQOL in Chronic Hepatitis C Patients. <i>Journal of Clinical Psychology in Medical Settings</i> , 2003 , 10, 41-49	2	9
26	Acute Liver Failure in the United States. <i>Annals of Internal Medicine</i> , 2003 , 139, 1045	8	4
25	NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2002 , 36, 1349-1354	11.2	258
24	Noninvasive monitoring of patients with chronic hepatitis C. <i>Hepatology</i> , 2002 , 36, S57-S64	11.2	109
23	Noninvasive monitoring of patients with chronic hepatitis C. <i>Hepatology</i> , 2002 , 36, S57-64	11.2	73
22	Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. <i>Liver Transplantation</i> , 2002 , 8, 433-9	4.5	102
21	Combination of HBIG and lamivudine-resistant mutations: a formula for trouble?. <i>Liver Transplantation</i> , 2002 , 8, 1082-4	4.5	3
20	Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. <i>Liver Transplantation</i> , 2002 , 8, 1165-74	4.5	131
19	Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. <i>Annals of Internal Medicine</i> , 2002 , 137, 947-54	8	1499
18	High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trial. <i>Journal of Clinical Gastroenterology</i> , 2002 , 34, 177-82	3	6
17	Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. <i>Journal of Hepatology</i> , 2002 , 36, 401-7	13.4	93
16	Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. <i>Gastroenterology</i> , 2002 , 123, 719-27	13.3	220
15	Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. <i>Psychosomatics</i> , 2002 , 43, 378-85	2.6	36
14	Computed tomography appearances of hypervascular hepatic tumors after percutaneous radiofrequency ablation therapy. <i>Current Problems in Diagnostic Radiology</i> , 2002 , 31, 105-11	1.6	19

13	Hepatitis B infection in patients with acute liver failure in the United States. Hepatology, 2001, 33, 972-	611.2	33
12	Outcome of liver transplantation for hepatitis B: report of a single centerN experience. <i>Liver Transplantation</i> , 2001 , 7, 724-31	4.5	13
11	Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2001 , 96, 170-8	0.7	78
10	Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2737-44	0.7	87
9	A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. <i>Liver Transplantation</i> , 2001 , 7, 504-10	4.5	51
8	Acute liver failure. Current Opinion in Gastroenterology, 2001 , 17, 291-8	3	13
7			
/	Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. <i>Digestive Diseases</i> , 2000 , 18, 107-	16.2	55
6	Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. <i>Hepatology</i> , 2000 , 31, 730-6	11.2	
	Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter,		
6	Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. <i>Hepatology</i> , 2000 , 31, 730-6 Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The		123
5	Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. <i>Hepatology</i> , 2000 , 31, 730-6 Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. <i>Liver Transplantation</i> , 1999 , 5, 480-4 Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in	11.2	123 64

Approach to the Patient with Acute Liver Failure114-135